Akebia Therapeutics Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Akebia Therapeutics de 71.4% y 27.1% respectivamente, mientras que el BPA crecerá en un 70.8% al año.

Información clave

71.4%

Tasa de crecimiento de los beneficios

70.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.4%
Tasa de crecimiento de los ingresos	27.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	13 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%

Nov 08

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Aug 02

Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)

Apr 02

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise

Mar 19

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Jan 05

Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump

Jun 23

Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?

Mar 02

Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky

Oct 07

Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher

Aug 10

Akebia regains rights to kidney disease therapy after termination of deals with Otsuka

Jun 30

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:AKBA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	245	34	N/A	N/A	2
12/31/2025	178	-67	N/A	N/A	3
12/31/2024	155	-65	N/A	N/A	2
9/30/2024	170	-46	-39	-39	N/A
6/30/2024	174	-40	-39	-39	N/A
3/31/2024	187	-43	-25	-25	N/A
12/31/2023	195	-52	-23	-23	N/A
9/30/2023	194	-59	-76	-76	N/A
6/30/2023	201	-98	-35	-35	N/A
3/31/2023	271	-58	-69	-69	N/A
12/31/2022	292	-94	-73	-73	N/A
9/30/2022	294	-158	-81	-81	N/A
6/30/2022	294	-163	-171	-171	N/A
3/31/2022	221	-276	-204	-204	N/A
12/31/2021	212	-282	-253	-253	N/A
9/30/2021	211	-299	-221	-221	N/A
6/30/2021	222	-300	-192	-192	N/A
3/31/2021	259	-392	-92	-92	N/A
12/31/2020	295	-385	-111	-110	N/A
9/30/2020	308	-391	-172	-172	N/A
6/30/2020	340	-386	-136	-134	N/A
3/31/2020	351	-268	-214	-209	N/A
12/31/2019	335	-280	-264	-257	N/A
9/30/2019	325	-245	-246	-239	N/A
6/30/2019	286	-217	-267	-262	N/A
3/31/2019	234	-193	-218	-215	N/A
12/31/2018	208	-144	-99	-97	N/A
9/30/2018	238	-68	-41	-40	N/A
6/30/2018	227	-65	N/A	-82	N/A
3/31/2018	206	-53	N/A	-67	N/A
12/31/2017	181	-74	N/A	-56	N/A
9/30/2017	92	-127	N/A	56	N/A
6/30/2017	51	-140	N/A	82	N/A
3/31/2017	22	-154	N/A	31	N/A
12/31/2016	2	-136	N/A	58	N/A
9/30/2016	N/A	-118	N/A	-61	N/A
6/30/2016	N/A	-101	N/A	-41	N/A
3/31/2016	N/A	-76	N/A	-27	N/A
12/31/2015	N/A	-61	N/A	-52	N/A
9/30/2015	N/A	-51	N/A	-39	N/A
6/30/2015	N/A	-41	N/A	-35	N/A
3/31/2015	N/A	-38	N/A	-30	N/A
12/31/2014	N/A	-124	N/A	-27	N/A
9/30/2014	N/A	-123	N/A	-23	N/A
6/30/2014	N/A	-120	N/A	-21	N/A
3/31/2014	N/A	-164	N/A	-16	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que AKBA sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que AKBA sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que AKBA sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (27.1% al año) de AKBA crezcan más rápidamente que los del mercado US (9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (27.1% al año) de AKBA crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de AKBA se prevé que sea elevada dentro de 3 años.

Akebia Therapeutics Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates decrease by 12%

No longer forecast to breakeven

Akebia Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2024

Consensus estimates of losses per share improve by 14%

Consensus revenue estimates decrease by 13%

No longer forecast to breakeven

Recent updates

Akebia Therapeutics, Inc. Announces Vadadustat Alternative Dosing Study Results

Consensus revenue estimates decrease by 12%

New major risk - Financial position

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%

Akebia Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Akebia Therapeutics, Inc. Announces Seven Poster Presentations at ASN Kidney Week 2024

Akebia Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

New major risk - Financial position

Second quarter 2024 earnings: EPS exceeds analyst expectations

No longer forecast to breakeven

Akebia Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2024

Akebia Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Akebia Therapeutics, Inc. Provides Update on Continued Momentum of Commercial Launch of Vafseo (Vadadustat) Tablets

Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Chief Financial Officer

Consensus estimates of losses per share improve by 14%

Consensus revenue estimates decrease by 13%

First quarter 2024 earnings released: US$0.088 loss per share (vs US$0.14 loss in 1Q 2023)

Akebia Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Insufficient new directors

Akebia Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

New minor risk - Profitability

No longer forecast to breakeven

Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)

Akebia Therapeutics, Inc. Receives FDA Approval of Vafseo (vadadustat) Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise

Full year 2023 earnings: EPS exceeds analyst expectations

Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024

Akebia Therapeutics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

CEO, President & Director recently sold US$74k worth of stock

CEO, President & Director notifies of intention to sell stock

Price target increased by 12% to US$4.33

CEO, President & Director recently sold US$78k worth of stock

Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Forecast to breakeven in 2026

Forecast to breakeven in 2025

Price target increased by 29% to US$3.88

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akebia Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Akebia Therapeutics, Inc. Announces Five Poster Presentations at ASN Kidney Week 2023

Akebia Therapeutics, Inc. Revises Revenue Guidance for the Year 2023

Akebia Therapeutics, Inc. to Report Q2, 2023 Results on Aug 25, 2023

Akebia Therapeutics, Inc. announced delayed 10-Q filing

Akebia Therapeutics, Inc. Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia®? (ferric Citrate) for In-Center and Home Dialysis Patients

Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump

Akebia Therapeutics, Inc. Announces Swissmedic Approval of Vafseo Vadadustat

Akebia Therapeutics, Inc. Announces Executive Changes

Senior VP & COO recently sold US$117k worth of stock

Consensus estimates of losses per share improve by 15%

Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Akebia Therapeutics, Inc. Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

Principal Accounting Officer recently sold US$68k worth of stock

Insider notifies of intention to sell stock

Consensus EPS estimates upgraded to US$0.33 loss

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akebia Therapeutics, Inc. Affirms Revenue Guidance for the Year 2023

Price target increased by 23% to US$2.00

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CEO, President & Director recently sold US$81k worth of stock

Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?

Akebia Therapeutics, Inc. Receives Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA

Akebia Therapeutics, Inc. Announces Executive Changes

Insufficient new directors

Akebia Therapeutics, Inc. Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Akebia Therapeutics, Inc. Affirms Revenue Guidance for the Year 2022

Akebia Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022